Expression of pGSK-3α/β Tyr279/216 and XIAP proteins in cholangiocarcinoma and their clinical significance.
- Author:
Jie-wei XU
1
;
Fan ZHOU
;
Gui-xing JIANG
;
Cheng-yang CHEN
;
Jing-jing WANG
;
Li-ping CAO
Author Information
- Publication Type:Journal Article
- MeSH: Bile Duct Neoplasms; metabolism; pathology; surgery; Bile Ducts, Intrahepatic; Carcinoembryonic Antigen; blood; Cholangiocarcinoma; metabolism; pathology; surgery; Female; Follow-Up Studies; Glycogen Synthase Kinase 3; metabolism; Glycogen Synthase Kinase 3 beta; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Survival Rate; X-Linked Inhibitor of Apoptosis Protein; metabolism
- From: Chinese Journal of Oncology 2013;35(5):366-371
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expressions of the active form of glycogen synthase kinase-3(GSK-3)-pGSK-3α/β (Tyr279/216) and its downstream moleculor X-linked inhibitor of apoptosis protein (XIAP) in cholangiocarcinoma and to analyze their correlation with clinicopathological and survival significance.
METHODSImmunohistoehemistry was used to detect the expressions of the active form of GSK-3- pGSK-3α/β (Tyr279/216) and its downstream moleculor XIAP proteins in 50 cholangiocarcinoma tissues and 20 normal bile duct tissues.
RESULTSThe positive rates of pGSK-3α/β (Tyr279/216) and XIAP were 62.0% and 68.0% in cholangiocarcinoma, and 10.0% and 25.0% in normal bile duct tissues, respectively. The intensity of pGSK-3α/β (Tyr279/216) and XIAP expressions in cholangiocarcinoma were significantly higher than that in the normal bile duct tissues (P < 0.001), and there was a significant correlation between pGSK-3α/β (Tyr279/216) and XIAP expressions (r = 0.544, P < 0.001). The expression of pGSK-3α/β(Tyr279/216) protein in cholangiocarcinoma was associated with TNM stage (P = 0.042), histological grade (P = 0.031), whereas the expression of XIAP protein in cholangiocarcinoma was correlated with CEA level (P = 0.006). Patients with positive expression of pGSK-3α/β (Tyr279/216) and XIAP demonstrate a significantly worse prognosis than that of patients with negative expression of pGSK-3α/β (Tyr279/216) and XIAP for overall survival (P = 0.002, P = 0.018). Multivariate survival analysis revealed that positive pGSK-3α/β (Tyr279/216) expression provided significant independent prognostic value for overall survival (P = 0.002).
CONCLUSIONSThe expressions of pGSK-3α/β(Tyr279/216) and XIAP proteins were significantly associated with the development and progression of cholangiocarcinoma. pGSK-3α/β(Tyr279/216) may be an important prognostic factor for survival of patients with cholangiocarcinoma.
